BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30126931)

  • 1. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.
    Itzykson R; Crouch S; Travaglino E; Smith A; Symeonidis A; Hellström-Lindberg E; Sanz G; Čermák J; Stauder R; Elena C; Germing U; Mittelman M; Langemeijer S; Mądry K; Tatic A; Holm MS; Almeida AM; Savic A; Šimec NG; Luño E; Culligan D; Guerci-Bresler A; Malcovati L; van Marrewijk C; Bowen D; de Witte T; Fenaux P;
    Blood Adv; 2018 Aug; 2(16):2079-2089. PubMed ID: 30126931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
    Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
    Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
    de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
    Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
    Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
    Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
    Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
    Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.
    Creignou M; Bernard E; Gasparini A; Tranberg A; Todisco G; Moura PL; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Elena C; Ferrari J; Gallì A; Pozzi S; Malcovati L; Edgren G; Crowther MJ; Jädersten M; Papaemmanuil E; Hellström-Lindberg E
    J Intern Med; 2024 Jul; 296(1):53-67. PubMed ID: 38654517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
    Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry.
    Kawabata H; Tohyama K; Matsuda A; Araseki K; Hata T; Suzuki T; Kayano H; Shimbo K; Zaike Y; Usuki K; Chiba S; Ishikawa T; Arima N; Nogawa M; Ohta A; Miyazaki Y; Mitani K; Ozawa K; Arai S; Kurokawa M; Takaori-Kondo A;
    Int J Hematol; 2017 Sep; 106(3):375-384. PubMed ID: 28497239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
    Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
    Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC; Wong SAY; Leitch HA
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
    Buckstein R; Wells RA; Zhu N; Leitch HA; Nevill TJ; Yee KW; Leber B; Sabloff M; St Hilaire E; Kumar R; Geddes M; Shamy A; Storring J; Kew A; Elemary M; Levitt M; Lenis M; Mamedov A; Zhang L; Rockwood K; Alibhai SM
    Br J Haematol; 2016 Jul; 174(1):88-101. PubMed ID: 26991631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.